Morgan Stanley lifts price targets on five companies, including Cheniere and Cencora
Morgan Stanley kept its ratings on Arxis, Cheniere, Cheniere Energy Partners, Cencora and Cardinal Health and raised their price targets. Source: TradingView, citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
On October 30, Morgan Stanley kept its ratings on several companies and lifted their price targets, according to TradingView, which cites Benzinga data. The list covers Arxis, Cheniere Energy, Cheniere Energy Partners, Cencora and Cardinal Health.
For Arxis the bank kept an Overweight rating and moved its target from 62 to 66 dollars, a gain of 6.5%. Cheniere Energy also stays at Overweight, with its target rising from 310 to 322 dollars, or 3.9%. Cencora, also at Overweight, got a target of 377 dollars versus 346, a 9.0% increase. Cardinal Health, at Overweight, saw its target go from 265 to 286 dollars, up 7.9%.
Cheniere Energy Partners keeps an Equal-Weight rating, and its target edged up from 62 to 63 dollars, a 1.6% change. That target implies a 5.7% decline from the October 29 close of 66.83 dollars.
why it matters
Changes like these are routine analyst work and reflect one bank's view rather than a shift in the market as a whole. For energy and healthcare shares, company fundamentals and demand matter more than individual target revisions. The news is routine and does not by itself point prices in any direction.
tags
instruments
sources
- Morgan Stanley maintains Arxis at Overweight, raises price target to $66 from $62 — TradingView, 30 October 2026 at 17:42 UTC
- Morgan Stanley maintains Cheniere Energy Partners at Equal-Weight, raises price target to $63 from $62 — TradingView, 30 October 2026 at 17:56 UTC
- Morgan Stanley maintains Cheniere Energy at Overweight, raises price target to $322 from $310 — TradingView, 30 October 2026 at 17:55 UTC
- Morgan Stanley maintains Cencora at Overweight, raises price target to $377 from $346 — TradingView, 30 October 2026 at 17:54 UTC
- Morgan Stanley maintains Cardinal Health at Overweight, raises price target to $286 from $265 — TradingView, 30 October 2026 at 17:51 UTC
- Morgan Stanley maintains Gilead Sciences at Overweight, raises price target to $183 from $163 — TradingView, 30 October 2026 at 18:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗